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White adipose tissue is one of the largest organs of the body. It plays a key role in
whole‐body energy status and metabolism; it not only stores excess energy but also
secretes various hormones and metabolites to regulate body energy balance. Healthy
adipose tissue capable of expanding is needed for metabolic well‐being and to pre-
vent accumulation of triglycerides to other organs. Mitochondria govern several
important functions in the adipose tissue. We review the derangements of mitochon-
drial function in white adipose tissue in the obese state. Downregulation of mito-
chondrial function or biogenesis in the white adipose tissue is a central driver for
obesity‐associated metabolic diseases. Mitochondrial functions compromised in obe-
sity include oxidative functions and renewal and enlargement of the adipose tissue
through recruitment and differentiation of adipocyte progenitor cells. These changes
adversely affect whole‐body metabolic health. Dysfunction of the white adipose tis-
sue mitochondria in obesity has long‐term consequences for the metabolism of adi-
pose tissue and the whole body. Understanding the pathways behind mitochondrial
dysfunction may help reveal targets for pharmacological or nutritional interventions
that enhance mitochondrial biogenesis or function in adipose tissue.
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Obesity is a global and rapidly increasing problem, tripled since 1975
by WHO 2018 standards in developed countries. Obesity is also
extremely difficult to treat. A key defining feature of obesity is an adi-
pose tissue dysfunction, which is considered to be a major contribu-
tor to the development of obesity‐related metabolic problems,1,2
such as metabolic syndrome, insulin resistance, hypertension,
dyslipidaemia, and fatty liver. The underlying pathological mechanisms
that impair adipose tissue function in obesity are incompletely under-
stood, but in the light of recent scientific advances, it may be con-
nected to insufficient storage capacity or impaired function of
mitochondria, or both.wileyonlinelibrary.com/jouMitochondria are the energy centres of adipocytes and are
involved in many of their key metabolic functions including ATP pro-
duction, fatty acid synthesis and oxidation, and the triglyceride bal-
ance of the cell. Although adipose tissue was long considered as an
inert reservoir of fat with low abundance of mitochondria, adipose tis-
sue and its active mitochondria have recently emerged as one of the
central regulators influencing whole‐body metabolism.1,3,4 Impair-
ments in adipocyte mitochondrial function are associated with meta-
bolic diseases and the development of obesity‐related disorders.3-6
Better understanding on the dysfunction of adipose tissue mitochon-
dria may yield insights on how the metabolic complications of obesity
could be reversed. In this review, we concentrate on the metabolic
processes in white adipose tissue that are regulated by mitochondria© 2019 World Obesity Federationrnal/obr 1 of 23
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on obesity and adipose tissue.2 | ADIPOSE TISSUE
White adipose tissue is one of the largest organs of the body. Approx-
imately 10% to 20% of total body weight in lean adults is white adi-
pose tissue, but in individuals with obesity, the amount can increase7
up to 40% to 70%. By harvesting excess lipids and glucose from the
circulation, it protects other tissues from the pathological accumula-
tion of triglycerides.2,8 When this storage capacity is disrupted, lipids
may spill over into ectopic sites like internal organs and vasculature
resulting in low‐grade inflammation, insulin resistance, and metabolic
problems.2,8,9 Intriguingly, both a total lack of adipose tissue in
lipodystrophies and an unhealthy excess of adipose tissue in obesity
lead to the same complications, including liver fat accumulation and
insulin resistance.2,8 Moreover, adipose tissue is an active endocrine
organ that regulates many metabolic responses at the whole‐body
level through adipocytokines.10 Changes in the main adipokines have
been implicated in many obesity‐related metabolic problems, such as
type 2 diabetes, metabolic syndrome, and cardiovascular diseases.
Adipose tissue consists of adipocytes and a matrix, which includes
collagen, blood and lymphatic vessels, and the stromal vascular frac-
tion of adipose tissue with endothelial cells, smooth muscle cells,
immune cells, adipocyte precursor cells (preadipocytes), and mesen-
chymal stem cells.11,12 Approximately 75% of adipose tissue weight
and 95% of an adipocyte consist of triglycerides. The main depots of
white adipose tissue are subcutaneous (80% to 90% of body fat), vis-
ceral (10% of body fat), and ectopic (intrahepatic, intramuscular, and
intrapancreatic) fat.13,14 Different adipose depots have differences in
capacity for adipocytokine secretion and cell type composition.15,16
In addition to white adipose tissue, also brown adipose tissue
(BAT) and beige/brite adipose tissue (having mixed characteristics of
both white and brown adipose cells) in humans exist.17-19 BAT has a
distinctive brown colour, which originates from the high iron and cyto-
chrome content of the dense network of mitochondria and vascula-
ture within the tissue.20 In contrast to the large unilocular
triglyceride droplets in white adipocytes, brown adipocytes are com-
posed of small, multilocular lipid droplets. BAT is the site of
nonshivering thermogenesis, where the brown adipocyte‐specific pro-
tein, uncoupling protein‐1 (UCP1), physiologically uncouples the respi-
ratory chain to generate heat, and its mitochondria could thus “burn”
away fat.17 An extensive previous research shows that BAT function
is impaired and its activity reduced in obesity.21,22 Cold‐induced BAT
glucose uptake and stimulation of blood flow are reduced in individ-
uals with obesity23 as well as glucose uptake rates into BAT lower in
both individuals with obesity and with type 2 diabetes.24 Studies have
also shown that animals with more BAT are more resistant to obesity
and type 2 diabetes.25,26 However, as the amount of BAT in human
adults is very low, the clinical significance and contribution of BAT
to energy expenditure are still debated.27 There is active research,
reviewed elsewhere, on the possibilities of inducing “browning” ofwhite adipose tissue or BAT function to treat obesity and its metabolic
outcomes.27-29
This review concentrates on the mitochondria of white adipose
tissue.3 | MITOCHONDRIA
Mitochondria are essential for key adipose tissue functions (Figure 1).
Mitochondria produce energy in the form of ATP through oxidative
phosphorylation (OXPHOS), generate substrates for cell metabolism
(eg, de novo fatty acid synthesis), regulate lipid turnover, and control
the generation of new adipocytes and adipokine secretion.3,30
Mitochondria are double‐membrane organelles with an outer and
an inner membrane and an intermembrane space. The inner mem-
brane is folded into cristae and surrounds a mitochondrial matrix,
where many chemical reactions of energy metabolism take place.
Mitochondria possess their own genome, a circular mitochondrial
DNA (mtDNA), which encodes 13 proteins critical for OXPHOS and
two ribosomal and 22 transfer RNAs required for mitochondrial ribo-
somes and translation, respectively.31,32 In addition, over one thou-
sand mitochondrial proteins, including essential proteins of
OXPHOS, mitochondrial translation, and other mitochondrial pro-
cesses are encoded by nuclear DNA.31,33,343.1 | Mitochondrial oxidative energy metabolism
The main energy derivation pathways of the cell, including pyruvate
oxidation, fatty acid β‐oxidation, the tricarboxylic acid (TCA) cycle,
and OXPHOS, occur in mitochondria (Figure 1).35
In aerobic energy production through OXPHOS, high‐energy elec-
trons (derived from substrate oxidation) are transferred through the
electron transport chain in the inner mitochondrial membrane (com-
plexes I‐IV of the OXPHOS system). The electron transport is coupled
with proton pumping at complexes I, III, and IV, generating an electro-
chemical potential difference across the inner membrane. The energy
of the gradient is utilized by complex V (ATP synthase) to phosphory-
late ADP to ATP.36
The TCA cycle is the final common oxidative pathway for all sub-
strates (carbohydrates, fatty acids, and amino acids) and generates
the high‐energy electron carriers (NADH and FADH2) that supply
OXPHOS, energy compounds ATP and GTP, and metabolites needed
as carbon skeletons for many biosynthetic processes of the cell, such
as de novo fatty acid synthesis.
Pyruvate derived from glucose is transported to the mitochondria
and oxidized in the matrix yielding acetyl‐CoA. The pyruvate dehydro-
genase complex catalyses the reaction and controls the amount of
acetyl‐CoA fed into the TCA cycle.
Free fatty acids (FFAs) are metabolized, esterified, or β‐oxidized in
adipocyte mitochondria. The long‐chain fatty acids are transported
from the cell cytosol into the mitochondrial matrix by carnitine
palmitoyltransferases (CPTs; CPT1, CACT, and CPT2).37 β‐oxidation
of the fatty acids produces acetyl‐CoA, which enters the TCA cycle.
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leucine, and valine) also occurs in mitochondria. Branched‐chain amino
acid aminotransferase (BCAT) forms α‐ketoacids (BCKAs) from BCAAs
via both cytosolic (BCATc, BCAT1) and mitochondrial (BCATm,
BCAT2) isoenzymes.38 The BCKAs are transported into mitochondria,
where they are decarboxylated by the mitochondrial branched‐chain
α‐ketoacid dehydrogenase (BCKD) complex. Finally, the products are
used in the TCA cycle.
3.2 | Energy‐status–dependent regulation of
mitochondria
By changing the morphology, distribution, and mass of mitochondria,
the cell adapts to different energetic and metabolic demands.39 Mito-
chondria are remodelled by fusion and fission, and changes in their
rate of biogenesis and distribution in the cell are frequent.40,41 Studies
on mitochondrial remodelling in adipose tissue are, however, sparse.
Mitochondrial network fragmentation and fission appears to improve
mitochondrial bioenergetics and make adipose tissue more insulin sen-
sitive.42 This is in contrast to skeletal muscle, where fission contrib-
utes to insulin resistance.43
The energy status of the cell is signalled through the NAD+:
NADH ratio, the AMP:ATP ratio, and acetyl‐CoA levels,44,45 whichFIGURE 1 Normal mitochondrial function in adipose tissue. Mitochon
factors. Most of the regulators are under the influence of PGC‐1α (in nuc
enhance mitochondrial biogenesis and function. MtDNA (green circle) enc
subunits, in grey) and for the OXPHOS complexes (in the mitochondrial me
mitochondrial ribosomes. Glucose, FFA, and BCAAs derived from nutrients
and other maintenance functions of the cell. Glucose is converted into pyr
cycle (dotted line, circle) for the production of ATP and GTP, NADH and F
enters beta‐oxidation and acetyl‐CoA further to TCA cycle. BCAAs are cat
complex frees acetyl‐CoA into theTCA cycle. Citrate is used for biosyntheti
precursor for lipogenesis as malonyl‐CoA, which also inhibits beta‐oxidation
T‐line, inhibition; green area, mitochondrion; yellow area, cell nucleussense the signals of mitochondrial activity. AMP‐activated protein
kinase (AMPK) is activated when AMP levels are high. This induces
oxidative phosphorylation and suppresses cell growth and prolifera-
tion.45 NAD+‐dependent deacetylase sirtuin 1 (SIRT1) is activated
when NAD+ levels are high, and this upregulates mitochondrial mass,
ATP generation, and nutrient oxidation. Both AMPK and SIRT1 acti-
vate the peroxisome proliferator‐activated receptor gamma coactiva-
tor 1 alpha (PGC‐1α). PGC‐1α is one of the main inducers of
mitochondrial oxidative metabolism, has a major role in mitochondrial
biogenesis,46 and interacts with many mitochondria‐related transcrip-
tion factors.47 In energy excess, PGC‐1α is acetylated and silenced.
Caloric restriction leads to PGC‐1α activation through SIRT1.48 An
activated PGC‐1α induces oestrogen‐related receptor α (ERRα) and
GA‐binding protein α (GABPα), which increase the function of the
OXPHOS complexes including cytochrome c and ATP synthase.49,50
PGC‐1α enhances nuclear respiratory factor 1 (NRF‐1), which is
needed for the induction of mitochondrial biogenesis51 and TFAM,
which controls mtDNA stability and the transcription of mtDNA‐
encoded genes.52 Transcription factor Forkhead box O 1, FOXO1,
enhances adipogenesis53 and controls adipocyte stress response.54
Also, mitochondrial DNA methylation may be a control factor of
mitochondria, although recent studies have challenged its existence
altogether.55,56dria (in green) are regulated by various nuclear‐related transcription
leus, yellow background). In normal conditions, transcription factors
odes proteins critical for mitochondrial ribosomes (12S and 16S
mbrane, in grey). The translation of these proteins is processed in the
(above the two lines, cell surface) are used for the energy production
uvate via glycolysis, and pyruvate‐derived acetyl‐CoA enters the TCA‐
ADH2, as well as TCA‐metabolites, like citrate. FFA‐derived acyl‐CoA
abolized via BCAT1 in cytosol and BCAT2 in mitochondria. BCKD
c processes of the cell, like production of other TCA metabolites and as
through CPT1 transporters. Mark explanations: an arrow, induction; a
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WHITE AT IN HEALTH AND IN OBESITY
4.1 | Mitochondrial oxidative metabolism in white
AT is altered in obesity
In recent decades, altered mitochondrial oxidative metabolism has
emerged as a molecular hallmark of obese adipose tissue (Figure 2).
Reduction of mitochondrial oxidative metabolism in adipose tissue
in obesity57,58 and in diabetes59 has been demonstrated in several ani-
mal studies: In diet‐induced or genetic mouse models of obesity, lim-
ited OXPHOS capacity, measured by maximal respiration capacity
and cell respiratory control ratios via cell respirometer, was observed
in white adipocytes, both in the absence and the presence of impaired
glucose tolerance.58 The authors concluded that impairments in mito-
chondria relate to obesity, not to glucose intolerance.58 Mitochondria‐
related transcription was reduced, and mitochondrial staining, DNA
quantification, and measurements of citrate synthase activity revealed
reduced mitochondrial biogenesis in both obesity and diabetes.60 The
gene transcripts encoding mitochondrial proteins were decreased in
obese mice without diabetes.57 After treatment with rosiglitazone,
half of the genes were upregulated, and the change was accompanied
by an increase in mitochondrial mass.57 However, another study found
reduced levels of OXPHOS mitochondrial protein subunits, cellular
mitochondrial DNA content by qPCR, oxygen consumption by cell res-
pirometer, and number of mitochondria by MitoTracker staining and
electron microscopy in diabetic, but not obese mice.59
Also, several human studies have linked obesity to mitochondrial
dysfunction and to impaired glucose and lipid metabolism in adipose
tissue.3,4,30 We have previously shown that mtDNA amount and gene
expression levels of mitochondria‐related pathways are downregu-
lated in co‐twins with obesity compared with their co‐twins who are
lean, a rare study setting that distinguishes the acquired features of
obesity from potential genetic effects.61 Moreover, we have demon-
strated downregulation of mitochondrial biogenesis in these twins
with obesity compared with their lean identical co‐twins by reduced
expression of genes encoding for mitochondrial proteins, expression
of PGC‐1α, mtDNA amount, expression levels of mtDNA‐encoded
transcripts and mitochondrial ribosomal protein subunits, and, finally,
reduced levels of OXPHOS complex subunits.62 The reduced expres-
sion of nuclear‐encoded mitochondria‐related genes, PGC‐1α, and
reduction of mtDNA‐encoded transcripts were recapitulated in iso-
lated primary mature adipocytes of the identical twins and the
reduced levels of OXPHOS protein subunit levels in the adipocytes
of unrelated individuals with obesity versus lean individuals.63 In
within‐pair extensive genome‐wide DNA methylation analysis, we
have previously identified 17 differentially methylated obesity‐
associated genes.64 These genes clustered to downregulated lipid
metabolism by mitochondria, downregulated adipogenic genes with
upregulated inflammation, and extracellular matrix (ECM) remodelling.
Additionally, we have shown hypermethylation in the co‐twins with
obesity in two CpG sites within the gene body of PGC‐1α, with meth-
ylation in one of the CpG sites correlating with PGC‐1α expression.62imilar results have been obtained in studies of unrelated individ-
uals. Downregulation of mitochondrial mtDNA in individuals with obe-
sity has been shown by several studies,61,62,65-69 although not all.70-72
The expression of PGC‐1α73 and the activities of the OXPHOS com-
plexes I to IV, mitochondrial phosphate utilization, and mitochondrial
membrane potential74 were downregulated in subcutaneous adipose
tissue of patients with obesity, compared with lean controls. The
activities of the OXPHOS complexes were reduced in simple obesity
and in obesity with diabetes.74 Obesity also links to decreased levels
of OXPHOS complexes I and IV75 in adipocytes, decreased mitochon-
drial oxygen consumption rates in isolated adipocyte mitochon-
dria,71,75 and reduced oxygen consumption rates in preadipocytes
after beta‐adrenergic stimulation.71 A study with human
preadipocytes has revealed changes in the methylation pattern of
the preadipocytes obtained from individuals with obesity, with loss
of DNA methylation in selected regions, where adipogenesis, inflam-
mation, and immunosuppression were the most affected pathways.76
Proteomic studies revealed that BMI was inversely associated with
four important omental adipose tissue mitochondrial proteins—citrate
synthase, HADHA, LETM1, and mitofilin.77 A lower abundance of
mitochondrial proteins in subcutaneous adipose tissue has been
recorded in insulin resistance without the presence of obesity78 and
in visceral fat of individuals with type 2 diabetes.79 These studies sug-
gest changes in the mitochondrial proteome with metabolic disorders
in general, but exact studies on obesity have yet to be performed.
Primary mitochondrial defects in adipose tissue affect metabolic
health also in transgenic mice. The results here, however, seem more
pronounced and somewhat contradictory than in acquired obesity.
ATP depletion by knocking out the TCA enzyme fumarase hydroge-
nase in white and brown adipocytes resulted in low adipose mass,
small adipocytes, and protection against obesity, insulin resistance,
and fatty liver despite a high‐fat diet.80 Mice genetically overexpress-
ing prohibitin (needed in adipocyte differentiation) had enhanced
mitochondrial biogenesis and consequently developed obesity.69
These studies suggest that mitochondrial downregulation in adipose
tissue could be beneficial, raising the question if the downregulation
of mitochondria in obesity is a compensatory mechanism. However,
this may not be the case as in another study with an adipose‐specific
TFAM‐knockout mice model to simulate mitochondrial dysfunction,
the mice became lipodystrophic and developed mitochondrial dys-
function, fatty liver, insulin resistance, and hypertension.81 Neverthe-
less, the conditions in these primary genetic‐model studies are not
directly comparable with obesity in humans and mice, where mito-
chondrial downregulation relates to obesity and metabolic problems.
The mice in the studies had primary mitochondrial defects, while the
decrease of mitochondrial function occurring in obesity is milder, pos-
sibly involving many different aspects of mitochondrial function.4.2 | Fatty acid oxidation is impaired in obesity
Adipocytes both generate and oxidize lipids. During nutrient excess,
glucose metabolism and lipogenesis produce malonyl‐CoA, which
HEINONEN ET AL. 5 23ofinhibits the import of fatty acids to mitochondria through the CPT1
transporter, decreasing fatty acid oxidation. In low energy status, AMPK
activation decreases malonyl‐CoA,82 resulting in enhanced CPT1 activ-
ity and β‐oxidation. Sirtuins regulate AMPK and have lately emerged as
important modulators of lipid metabolism and fatty acid oxidation.83
In obesity, mitochondrial fatty acid oxidation is suggested to be
impaired,4 at least in subcutaneous adipose tissue.84 Obese rats have
impaired fat oxidation and reduced CPT1 mRNA levels in
intraabdominal adipose tissue.85 CPT1A overexpression in cultured adi-
pocytes in turn has enhanced fatty acid oxidation, improved insulin sen-
sitivity, and decreased inflammation.86 However, as only modest
activity of CPT1 in adipose tissue has been suggested, it has been
questionedwhether the changes in the levels of CPT1 have significance
in obesity.87 On the other hand, in mice study, an adipose‐specific
knockout of CPT2A of mitochondrial long‐chain fatty acid β‐oxidation
compromised fatty acid oxidation in adipose tissue but reduced high‐
fat diet‐induced oxidative stress, ROS production, and inflammation
compared with normal mice.88 These results may indicate that an intri-
cate balance of fatty acid oxidation may be needed—enough to prevent
excess accumulation of triglycerides in adipose tissue and FFA flux to
other tissues, but not in excess leading to inflammation in the tissue.4.3 | BCAA oxidation is downregulated in obesity
Adipose tissue is one of the main sites of mitochondrial BCAA catab-
olism.89 BCAAs function as nutrient signals of amino acids, total food
intake, and energy balance.90,91 They regulate insulin secretion, pro-
tein synthesis, and protein breakdown in adipose, liver, and muscle tis-
sues.90,91 Already in the 1970s, adipose tissue was suggested to be
important in the conversion of excess BCAA into fat92; the ability of
which was confirmed only in 2010.89
In insulin resistance and in obesity, downregulation of BCAA oxi-
dation enzymes and transcription of genes involved in BCAA oxidation
in adipose tissue has been reported several times (Figure 2),61,62,91,93-95
as have elevated levels of BCAAs in the blood stream.61,96 The BCAA
levels in circulation rise with decreased oxidation.89 Increased plasma
BCAA levels are associated with type 2 diabetes,97 insulin resis-
tance,98 metabolic syndrome and cardiovascular diseases.99,100 In con-
trast, BCAA‐rich diets in mice on high‐fat diet resulted in improved
glucose metabolism and lower body weight compared with controls
on high‐fat diet without BCAA supplement.101 The study, however,
did not measure serum BCAA levels. Interestingly, elevated plasma
levels of BCAA but improved insulin sensitivity and increased energy
expenditure were observed in all‐tissue BCATm‐knockout mice.102
Increased levels of BCAAs in circulation have been suggested to be
contributors to the development of insulin resistance through the
accumulation of mitochondriotoxic metabolites, which promote pan-
creatic β‐cell dysfunction, apoptosis, and stress signaling.90 Insulin
resistance has indeed been shown to result in increased protein deg-
radation in tissues,90 leading to increased levels of amino acids and
BCAAs in the circulation. Furthermore, persistent activation of the
mammalian target of rapamycin complex 1 (mTORC1) by BCAAsappears to lead to uncoupling of the insulin receptor from the insulin
signalling mediator (IRS‐1) and to further insulin resistance.90 It is
unknown if the same mechanisms are involved in adipose tissue.4.4 | Glucose oxidation is reduced in obesity
In high‐fat–fed mice, metabolites related to glucose oxidation in the
mitochondrial matrix are decreased, with a nearly 50% reduction in
the levels of 1,5‐anhydroglycitol (1,5‐AG), which is a marker of short‐
term glycaemic control in plasma.103 The levels of glucose‐6‐phosphate
of glycolysis were decreased, and the expression of Pdk4, an inhibitor of
mitochondrial pyruvate dehydrogenase activity, was diminished, sug-
gesting aberrant glucose oxidation with high‐fat diet.103
Mitochondrial glucose oxidation in adipose tissue is studied less in
humans, and there is not yet direct evidence on decreased oxidation
or increased glycolytic activity in human obesity. Comparisons
between male and female subjects have shown that preadipocytes,
but not mature adipocytes from female subjects, show higher mito-
chondrial to glycolytic activity in normoglycaemic conditions.104 When
challenged with extra glucose and insulin, preadipocytes from female
donors reduce their ATP‐linked mitochondrial respiration, possibly as
a marker of greater insulin sensitivity, with both male and female
preadipocytes increasing their glycolytic activity.104 This might indi-
cate changes in oxidative versus glycolytic activity with excess energy;
however, more studies are needed to draw conclusions on the subject.4.5 | Mitochondrial respiration and adipose tissue
oxygen levels
Mitochondrial energy metabolism in the cell is oxygen dependent. Adi-
pose tissue was previously suggested to be oxygen deprived in obe-
sity, as the adipocytes enlarge beyond the oxygen diffusion limit105
of approximately 100 μm. Hypoxia was considered as one of the
inducers of inflammation, because preadipocytes obtained from indi-
viduals with obesity cultured in hypoxic conditions secreted more
inflammatory markers.106 In rodent models of obesity, rapid weight
gain is accompanied with increased expression of genes related to
hypoxia, lower partial oxygen pressure, and an increase in hypoxic
areas in adipose tissue.107,108 Also, decreasing adipocyte oxygen con-
sumption and hypoxia by Ant2 knockdown in obese mice has led to
decreased inflammation and improved glucose tolerance.109 In human
obesity, oxygen pressure in adipose tissue has been reported as
reduced in individuals with obesity versus lean individuals.110 How-
ever, recent new studies have questioned the view of hypoxia in adi-
pose tissue in obesity. A study by Goossens et al has found increased
oxygen pressure in adipose tissue of individuals with obesity.111 The
latter study was matched for age, gender, presence of type II diabetes,
and ethnicity, and the results were later replicated in a weight‐loss
study by the same group, where 5‐week very low–calorie diet in indi-
viduals with obesity decreased adipose tissue oxygen pressure.112
Also, no significant differences have been found between persons
with obesity and lean persons in relation to secretion of the adipose
HEINONEN ET AL.6 23oftissue hypoxic markers lactate and pyruvate.113 Based on these
results, it has been suggested that the oxygen consumption of adipose
tissue is reduced in obesity, resulting in higher adipose tissue partial
oxygen pressure despite the lower blood supply.114 As mitochondrial
oxidative metabolism is an important consumer of cellular oxygen,
these studies can be considered as indirect evidence for low mito-
chondrial oxidative metabolism in adipose tissue in obesity.4.6 | Lipogenesis and lipolysis may be impaired in
obesity
Active mitochondria are needed in both lipogenesis and lipolysis.
Mitochondria are essential in generating the intermediary metabolites
needed for de novo fatty acid synthesis3 such as TCA‐cycle–derived
acetyl‐CoA for fatty acid synthesis and esterification into triglycerides
with glycerol‐3‐phosphate.115 In mouse studies, the rate of lipogene-
sis decreases with interventions that reduce mitochondrial ATP
generation.116,117 Conversely, the amount of mtDNA shows a strong
positive correlation with the rate of lipogenesis in human adipo-
cytes.65 Thus, mitochondrial dysfunction may be connected to
impaired lipogenesis.
During fasting, adipose tissue releases FFA by lipolysis via the
function of hormone‐sensitive lipase (HSL)118 and adipose triglyceride
lipase (ATGL).119 Lipolysis and mitochondrial ATP syntheses were first
shown to be coupled in 1975, when inhibitors of the electron trans-
port chain shut down catecholamine‐induced lipolysis.120
During exercise or fasting, persons with obesity appear to have a
lower capacity for lipolysis than lean persons, while in the fed state,
lipolysis is insufficiently suppressed due to the insulin resistance of
the adipose tissue, leading to hypertriglyceridemia.121 Hypertriglyc-
eridemia has a major role in the aetiology of insulin resistance.5,122
Nevertheless, mice with an ATGL and HSL full‐body knockout exhibit
increased fat mass and lipid accumulation in insulin‐sensitive tissues,
however with inconsistent results on the insulin sensitivity of the ani-
mals.123 Moreover, the levels of adipose tissue ATGL and HSL are
shown to be decreased in insulin‐resistant individuals with obesity.124
In human multipotent adipose stem cell (hMADS) adipocytes, a knock-
down or pharmacological inhibition of ATGL and HSL increased lipid
accumulation and insulin resistance and leads to reduced mitochon-
drial oxygen consumption and impaired PPARα signaling.125 The
authors of the human and hMADS studies suggest HSL and ATGL
deficiency as a compensatory mechanism, which tries to decrease lipid
flux into the circulation while simultaneously impairing adipocyte
function. Interestingly, inefficient lipolysis has recently been linked to
future weight gain and suggested to be a marker for identifying risk
individuals for the prevention of obesity.1264.7 | Adipokine secretion is altered in obesity
Adipocytes and adipose tissue matrix cells secrete a variety of
adipocytokines. These adipokines regulate energy intake and expendi-
ture, body weight, glucose and lipid metabolism, insulin sensitivity andinflammation,127,128 generation of preadipocytes,129 and the migration
of the cells in adipose tissue,130 acting as hormones, or in an autocrine
or paracrine fashion within adipose tissue.
Leptin and adiponectin are the main adipokines that are exclusively
secreted by adipocytes. Leptin decreases food intake and energy con-
sumption by acting on the hypothalamus and target tissues,131
increases insulin sensitivity,120 stimulates lipolysis by increasing cAMP
concentrations in the cell,132 and can activate inflammatory cytokine
secretion.133 However, apart from increasing cAMP concentrations,
direct data on the relationship between leptin and mitochondria in
the literature are sparse and still remain to be studied.
Adiponectin stimulates fatty acid oxidation, improves glucose
metabolism and insulin sensitivity, and decreases plasma FFA levels
in adipose tissue134 by inhibiting lipolysis.135 Adiponectin is also an
anti‐inflammatory molecule.136 A decrease or an increase in mitochon-
drial biogenesis directly inhibits or enhances adiponectin secretion and
synthesis in adipocytes.137 This is evidenced also by inhibition of the
electron transport chain or deletion of mitochondrial transcription fac-
tor A, which both lead to reduced adiponectin secretion.138 Further-
more, hypertrophied adipocytes with diminished mitochondrial
capacity have reduced synthesis of adiponectin.139 In adipose tissue,
adiponectin has been shown to block the mitochondrial apoptosis
pathway by activating AMPK signalling and inhibiting ER stress‐
induced apoptosis.140 These studies introduce adipocyte mitochon-
drial function as a potential target to restore adiponectin secretion
and levels in obesity and related metabolic disorders.4.8 | Mitochondria in adipogenesis
The renewal and maintenance of adipose tissue are achieved by
preadipocytes. These cells are derived from adipose tissue stem
cells,141,142 which reside in adipose tissue vascular stroma.142,143 Adi-
pogenesis consists of two main steps: commitment of a pluripotent
progenitor population to a preadipocyte lineage and terminal differen-
tiation, in which the preadipocytes differentiate into mature functional
adipocytes. Impairments in adipogenesis have been suggested to lead
to accumulation of ectopic fat and insulin resistance.2
Mitochondria are essential in adipocyte differentiation and adipo-
genesis.3 Mitochondrial biogenesis and adipogenesis are intertwined
processes tightly coordinated by the same transcription factors.
PPARγ,144 C/EBPα,144 CREB,3,145 oestrogen‐related receptor α
(ERRα),146 and PGC‐1α are all major regulators of both adipogenesis
and mitochondrial biogenesis147,148 of which specifically PPARγ is a
powerful inducer of adipogenesis. Mitochondrial biogenesis is thought
to be under the control of adipogenic gene expression.3,148 Various
mitochondrial modifications take place during adipogenesis,149 and
mitochondria provide the essential substrates necessary for lipogene-
sis during adipogenesis.115 A 20‐ to 30‐fold increase in the amount of
mitochondrial proteins has been recorded during adipocyte differenti-
ation,149 and the oxygen consumption of the preadipocytes increases
in parallel to increased mitochondrial biogenesis.149 The link between
adipogenesis and mitochondrial biogenesis is reinforced also by the
FIGURE 2 Mitochondrial dysfunction in adipose tissue in obesity. Steps leading to mitochondrial dysfunction: Downregulation of the nuclear
transcription factors (red text) results into downregulation of mitochondrial biogenesis (in red) and adipogenesis with reduced mtDNA amount
(red), reduced mitochondrial ribosomal transcripts (red), reduced OXPHOS transcripts and protein subunit levels (red). Reduction in the GLUT4
translocation (red) to adipocyte cell membrane reduces glucose uptake into adipose tissue and thus the levels of pyruvate available for TCA.
Excess FFAs (in bold text) impair beta‐oxidation (in red), with the production of excess ROS (bold) and possible intermediary oxidative metabolites.
These further derange cell functions. Changes in lipogenesis and lipolysis (in red) take place, favouring fat storage; however, with also impairments
in lipolysis. BCAA catabolism (in red) is downregulated yielding less Acetyl‐CoA available for TCA. Mark explanations: text in red, downregulated in
obesity; an arrow, induction; a T‐line, inhibition; bolded text, increased in obesity
HEINONEN ET AL. 7 23offact that the PPARγ agonist rosiglitazone induces alterations in mito-
chondrial morphology and density.57
Interestingly, BCAA catabolism and utilization of BCAA‐derived
carbon skeletons (through the TCA cycle) for fatty acid synthesis also
increase during the differentiation,150 potentially fuelling the pro-
cess.151 Mitochondrial metabolism of BCAAs also stimulates increase
in fat cell mass, adipose tissue lipid uptake, and differentiation by acti-
vating mTORC and thus PPARγ signaling.90,152
In animal studies, pharmacologically inhibiting complex I or the
ATP synthase inhibits the proliferation153 and differentiation of
preadipocytes in mice.154 In mouse 3T3‐L1 preadipocytes, mitochon-
drial dysfunction induced by a complex III inhibitor leads to abnormal
triglyceride accumulation, reduced expression of adipogenic markers,
and to impaired differentiation.145 In rat preadipocytes, inhibition of
complex I resulted in inhibition of preadipocyte differentiation with
reduced ATP synthesis and downregulated gene expression of fatty‐
acid synthase, LPL, PPARγ, C/EBPα, and SREBP‐1c.155
Adipogenesis and the enlargement of adipose tissue are seen as a
crucial mechanism that protects other tissues from triglyceride accu-
mulation, insulin resistance, and metabolic dysfunction.
4.9 | Mitochondria in adipocyte hypertrophy and
hyperplasia in obesity
Adipose tissue enlarges by adipocyte hypertrophy (increase in cell
size), hyperplasia (increase in cell number), or both (Figure 3).Mitochondria regulated lipogenesis and adipogenesis and thus may
affect the hypertrophy versus hyperplasia of the tissue. The number
of adipocytes in adipose tissue is determined by the differentiating
preadipocytes and the recruitment of mesenchymal stem cells for dif-
ferentiation.156 In general, cellular hypertrophy is associated with insu-
lin resistance,157-159 hepatic steatosis, dyslipidemia,160 elevated levels
of circulating inflammatory markers,161 increased inflammatory gene
expression,162 and increased number of macrophages in adipose tis-
sue.163,164 Hyperplasia in turn seems to preserve insulin sensitiv-
ity158,165 and a favourable secretion of signalling molecules in
adipose tissue.163
Adipocyte renewal and turnover—10% of the cells each year—
occurs throughout life, although the number of adipocytes in an indi-
vidual appears to be stable and determined early in adulthood.166 Adi-
pocyte number does not differ between co‐twins with obesity
compared with their lean MZ co‐twins, suggesting a strong genetic
control of this measurement.167 There is no significant increase in adi-
pocyte number in short‐term weight increase168 nor decrease follow-
ing long‐term weight loss.166
In individuals with obesity169 and individuals with type 2 diabe-
tes,170 reduced generation of preadipocytes has been proposed, indi-
cating defects in adipogenesis. In contrast, metabolically normal
individuals with obesity have elevated levels of proadipogenic factors
and lipid droplet proteins compared with metabolically compromised
individuals.171 Adipose stem cells isolated from human subjects with
obesity show reduced mitochondrial content, ability to proliferate,
FIGURE 3 Adipogenesis, adipocyte hypertrophy and hyperplasia. The capacity of adipose tissue to enlarge is determined by the number of
preadipocytes in the tissue and the capacity of preadipocytes to differentiate into adipocytes. Adipose tissue can enlarge by hypertrophy or
hyperplasia. In normal state (above the line; black text, black arrows), nuclear transcripts induce preadipocyte recruitment and differentiation into
adipocytes. Mitochondrial oxygen consumption and the amount of mitochondrial proteins increases. With increased fat mass, both hyperplasia
and mild hypertrophy occur, preserving insulin sensitivity and mitochondrial function in the tissue. In obesity, excess FFAs stress the capacity of
adipose tissue and its mitochondria. Nuclear transcripts inducing the differentiation of preadipocytes and mitochondrial function are
downregulated (red text), leading to impaired differentiation and less mitochondria in the tissue (red). This in turn leads to less hyperplasia and
increased hypertrophy of the cells (red arrows) leading to metabolic problems (red). However, some individuals with obesity appear to respond to
increased FFA load more like in the normal state (black, above the line), with increased hyperplasia rather than only hypertrophy, avoiding part of
the detrimental effects of fat accumulation. Mark explanations: red text, downregulated in obesity; black text, normal function; red arrows,
metabolically unwanted changes; black arrows, normal function
HEINONEN ET AL.8 23ofand telomerase length and activity, and adipose stem cells in culture
are less viable and more senescent than stem cells from lean
persons.172
Small adipocytes are generally regarded as metabolically healthier.
Their proportion is increased for example in lean co‐twins of obesity‐
discordant twins,167 and smaller adipocytes have been reported in
omental adipose tissue of individuals with morbid obesity but with
preserved insulin sensitivity173 and in individuals characterized as
“metabolically healthy” individuals with obesity,174 without features
of metabolic syndrome.175 In contrast, an expanded population of
small adipocytes and decreased expression of differentiation markers
in the insulin‐resistant versus insulin‐sensitive individuals with obesity
has been discovered, indicating potential defects in adipogenesis.176
Insulin stimulates adipocyte hypertrophy,177 but less hyperplasia.178
Thus, the authors proposed that insulin resistance may hinder the
hypertrophic effects of insulin with an impaired adipocyte differentia-
tion towards larger mature cells.176 However, based on the different
studies, the insulin‐sensitive persons with obesity, with a better adipo-
cyte differentiation capacity, may be protected from the adverse
effects of ectopic fat accumulation.
Arner et al have shown that subjects with a larger adipocyte vol-
ume than predicted for a given body fat mass (a hypertrophic adiposityphenotype) have lower rates of adipogenesis.179 In turn, high genera-
tion rates of adipocytes associate with a hyperplastic phenotype.179
After bariatric surgery, subjects with the hypertrophic obesity pheno-
type180 had the largest reductions in adipocyte size and gained most in
insulin sensitivity.159 Interestingly, the adipocyte morphology in these
latter studies was not associated with the amount of weight loss but
rather to its metabolic outcomes indicating that the adipogenic capac-
ity (regulated by mitochondria) of adipose tissue distinguishes the
metabolic outcomes of obesity and of weight loss. However, both
capacities—the hypertrophic and hyperplastic—seem to be needed
for metabolic well‐being.
We have previously associated large adipocyte volume to down-
regulation of mitochondria‐related pathways in adipose tissue and
these to the deterioration of metabolic profile in obesity.167 The “met-
abolically unhealthy” twins with increased liver fat content compared
with their leaner co‐twins had hypertrophied adipocytes and less
hyperplasia in their subcutaneous adipose tissue, with downregulation
of mitochondrial oxidative pathways.94 Our studies propose that some
individuals may be able to respond to long‐term energy excess with
hyperplasia, while others predominantly react by hypertrophy, leading
to differences in mitochondrial metabolism and the metabolic out-
comes of obesity. A study by Yin et al in 2014 found reduced
HEINONEN ET AL. 9 23ofmitochondrial respiratory capacity in individuals with obesity com-
pared with lean individuals, independent of adipocyte size.71 In
2015, Fisher et al also suggested that all adipocytes from an individual
with obesity or from a lean individual have the same oxidative profile,
independent of cell size, with obesity leading to impaired mitochon-
drial respiration in the cells.75 These findings support the idea that
obesity leads to deterioration of adipose tissue hyperplastic capacity
and mitochondrial function; the exact relationship of which still
requires further study.4.10 | Visceral vs subcutaneous AT mitochondria
The studies on mitochondria in humans are largely concentrated on
findings in subcutaneous adipose tissue, probably due to its easier
accessibility for studies.
The visceral adipocytes in normal‐weight rats contain more mito-
chondria than subcutaneous adipocytes.181 In mice, subcutaneous adi-
pocytes in turn seem to have a higher respiratory capacity than visceral
adipocytes.67 A high‐fat diet in mice decreased visceral adipocyte
mitochondrial capacity more than that of subcutaneous adipocytes,
with the development of glucose intolerance.67 In human studies, the
mtDNA content in visceral adipose tissue was reduced in patients with
diabetes but increased in patients with obesity compared with non‐
obese controls.72 Human subjects with obesity undergoing bariatric
surgery had twice the concentration of mitochondria per mass of tis-
sue in visceral versus subcutaneous fat, but visceral fat had smaller
cells to make up the same mass.182 Respiration rates were higher in
visceral than subcutaneous adipose tissue, but when normalized with
mtDNA content, visceral adipose tissue had lower respiration per
mitochondria and per adipocyte than subcutaneous adipose tissue.1824.11 | Mitochondrial oxidative metabolism and
insulin sensitivity
A link between adipocyte mitochondrial oxidative capacity and whole‐
body insulin sensitivity has been suggested by both rodent and human
studies.183 Insulin‐sensitive and insulin‐resistant patients with obesity
appear to differ in adipose tissue oxidative stress levels and in the
expression of genes related to mitochondrial function, SIRT1/Nampt
activity,111,173,184 and adipogenic capacity.94 In obesity‐discordant
twins, the “metabolically unhealthy” group presented with reduced
expression of mitochondria‐related pathways and reduced mtDNA
amount in subcutaneous adipose tissue with increased inflammation
and insulin resistance.94 These studies suggest an association between
preserved mitochondrial function and insulin sensitivity.
More mechanistic studies in rodents reveal that excess glucose and
fatty acids seem to lead to mitochondrial dysfunction. Mouse
preadipocytes exposed to high glucose and fatty acids exhibit
decreased mitochondrial size, decreased mitochondrial membrane
potential, and downregulation of the master mitochondrial regulator
PGC‐1α.185 Impaired glucose homeostasis, decreased PGC‐1α expres-
sion, and reduced mtDNA content in response to high‐fat feedinghave also been demonstrated in rats.186 High concentration of fatty
acids in 3T3‐L1 mouse adipocytes results in insulin resistance and in
decreased levels of FoxO1, an inducer of adipogenesis and mitochon-
drial biogenesis.54
The mechanism linking mitochondrial dysfunction to the develop-
ment of insulin resistance may involve the production of ROS. A high‐
fat diet in mice increased mitochondrial ROS, which were shown to
contribute to insulin resistance in adipose tissue,187 because genetic
upregulation of the antioxidant enzymeMCATwas sufficient to reduce
ROS damage and to preserve insulin signaling.187 In another mouse
study, high‐fat feeding resulted in increased ROS and mitochondrial
oxygen consumption rate and subsequently insulin resistance, which
later led to a reduction in mitochondrial biogenesis.188 Earlier studies
have also linked the increase in oxidative radicals O2 superoxide and
H2O2 to insulin resistance,
187,189,190 and a long‐term high‐fat diet is
associated with increased oxidative stress markers in humans and
mice.191 A recent study on 3T3‐L1 adipocytes and adipose tissue
revealed a mechanism for the latter relationship, where elevated mito-
chondrial oxidants rapidly impair insulin‐regulated GLUT4 translocation
and lead to insulin resistance in tissue.192 Furthermore, another study
in 3T3‐L1 preadipocytes demonstrated that reduction in mtDNA levels
and respiratory chain activity actually enhanced insulin signalling but
nevertheless caused impaired insulin responsiveness by decreasing
GLUT4 translocation on the cell surface.193
Taken together, these studies link mitochondrial oxidative activity
and particularly ROS generated in the electron transport chain to insu-
lin sensitivity. Excess fatty acids and glucose are the potential initia-
tors of mitochondrial problems. This idea is in line with studies
where lipid metabolites such as ceramide and diacylglyceroles (DAG)
cause insulin resistance and impair mitochondrial function by activat-
ing serine kinases.194-196 Furthermore, interventions that have com-
promised mitochondrial function by genetic193 or pharmacologic197
mechanisms have resulted in insulin resistance.
The connection between mitochondrial respiratory activity to insu-
lin resistance has not been replicable in all studies. A murine study
found reduced mitochondrial parameters in both obese and diabetic
mice60 and respiratory capacity in subcutaneous and visceral fat was
reduced in obese mice, independent of insulin resistance.58 No con-
nection between mitochondrial biogenesis and glucose homeostasis
was observed in a study on mouse adipocytes198 and no association
between type 2 diabetes and the activity of the mitochondrial
OXPHOS complexes in human visceral adipose tissue.1994.12 | Mitochondrial oxidative metabolism and
inflammation
Inflammation is closely linked to adipose tissue dysfunction in obe-
sity. Although downregulation of mitochondrial capacity and
increased inflammation frequently co‐occur in adipose tissue in obe-
sity,62,94,95,200,201 the order of the events is not clear. Mitochondrial
dysfunction can be both the cause and the consequence of
HEINONEN ET AL.10 23ofinflammation. However, many studies suggest that mitochondrial
dysfunction precedes inflammation in adipose tissue.
A study with diet‐induced obese mice showed increased activity of
pathways that favour fat storage and prevent lipid oxidation, with an
early decrease in citrate synthase activity and expression of Pgc1a,
with these changes preceding the inflammatory cell infiltration and
the decrease in mitochondrial abundance.103 FFA and glucose in high
quantities directly stimulate mitochondrial dysfunction185 and have
led to high levels of TNFα, ER stress, and increased ROS202,203 in
mouse 3T3‐L1 preadipocytes. The mechanisms by which mitochon-
drial dysfunction causes inflammation could include increased ROS
production, which together with intermediary metabolic com-
pounds204,205 predisposes to cell death and consequently to increased
immune cell infiltration.206 Accumulation of intermediary metabolic
compounds—protein carbonyls, lipid peroxidation products, and
malondialdehyde—together with increased ROS production and mito-
chondrial oxidative stress has been observed in adipose tissue of sub-
jects with obesity, with obesity and diabetes and non‐obese subjects
with diabetes compared with lean subjects.205 Expanding large adipo-
cytes (with potential mitochondrial dysfunction) express inflammatory
markers207,208 and release more chemokines207,208 and FFA, which
are able to recruit macrophages into adipose tissue and activateFIGURE 4 Mitochondrial dysfunction in relation to whole‐body metaboli
and lipolysis, oxidative phosphorylation, FFA oxidation and BCAA oxidation
Impaired mitochondrial biogenesis (an arrow from nucleus passing through
mitochondrial mtRNAs and rRNAs, PGC‐1α, OXPHOS subunits) is connecte
blocks the induction of adipogenesis by BCAA metabolites (a T‐line BCAA
increased inflammation and insulin resistance in adipose tissue. ROS also a
Inflammation further impairs mitochondrial biogenesis. Changes in the gen
membrane and make the tissue more prone to inflammatory cell infiltration.
(bold arrow). Mark explanations: red text, downregulated mitochondria‐rel
induction; a T‐line, inhibition; bolded arrows, main pathways leading to met
consumption of adipose tissue, increased insulin resistance and inflammatio
observed. These changes further connect with the accumulation of FFA to
resistance in the whole‐body level (oval, orange background)inflammatory pathways.209 Furthermore, mitochondria synthesize
phospholipids, which are responsible for the fluidity of the adipocyte
cell membrane,210 and membrane lipid modifications in humans have
been shown to recruit inflammatory cells into adipose tissue.211
Based on these studies, obesity may disrupt mitochondrial bal-
ance, leading to increased oxidative stress and increased inflamma-
tion in the adipose tissue. On the other hand, inflammation may
lead to further deterioration of mitochondria‐related metabolism in
the cells, as evidenced by studies where preadipocytes obtained from
mice212 or preadipocytes isolated from individuals with obesity213
have been treated with proinflammatory TNF‐α. However, more
studies are still needed on the exact causal relationship of mitochon-
drial dysfunction and inflammation in adipose tissue in obesity
(Figure 4).
4.13 | Methods to study mitochondria in adipose
tissue
There are many methods to study mitochondria. In this paragraph and
in Table 1, we briefly summarize the main methods that have been
used in white adipose tissue. On global level, the expression of genes
related to mitochondria has been studied via transcriptomics fromsm. In obesity, mitochondrial biogenesis and function with lipogenesis
(main mitochondrial pathways, marked in red) appear to be impaired.
mitochondria, presenting downregulation of mtDNA amount,
d with impaired adipogenesis. Downregulation of BCAA oxidation also
‐adipogenesis). Impaired OXPHOS produces excess ROS, leading to
ctivate the adipocytes to recruit macrophages into the tissue.
eration of phospholipids for cell surface reduce the fluidity of the cell
These changes lead to impaired mitochondrial biogenesis and function
ated transcripts or mitochondrial components in obesity; an arrow,
abolic derangements. As a result, impaired adipogenesis, lower oxygen
n, and reduced oxidative and metabolic functions of adipose tissue are


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HEINONEN ET AL. 13  23ofRNA isolated from adipose tissue or purified adipocytes.57,60-62,81,186
Mitocarta, a public inventory of 1158 human and mouse genes that
encode proteins with strong support of mitochondrial localization,34
can help with finding the transcripts related to mitochondria. Similarly,
proteomic studies by mass spectrometry determine the amount and
distribution of mitochondria‐related proteins of interest.77-79 Isolation
of DNA and the epigenetic studies has been used to determining the
activity or silencing via methylation of certain mitochondria‐related
genes.62,76
More targeted analyses can be made from mitochondria isolated
from the tissue.71,74,75 The mtDNA copy number in mitochondria by
qPCR may be determined by specifically targeted primers to evaluate
the mitochondrial DNA amount relative to nuclear DNA.61,62,65,67,186
As mitochondria may possess multiple copies of their genome, mtDNA
mass does not equal the number of mitochondria in the tissue. The
transcript levels of the mtDNA encoded genes can be studied by mt‐
RNA targeted quantitative RT‐PCRprimers.62,63 The levels of
mitochondria‐encoded protein subunits of the OXPHOS complexes
by western blot may be determined.58,62,63,75,81 Immunoblotting can
be used to study the levels of also other specific nuclear‐encoded
mitochondria‐related proteins.58,69,81,186
Mitochondrial staining by MitoTracker Green or other mitochon-
drial dyes for fluorescence microscopy determinations add to the
knowledge on mitochondrial morphology and distribution57,58,69,81
The ultrastructure of mitochondria have been further studied with
transmission electron microscopy.69
Studies assessing mitochondrial function directly in adipose tissue
or preadipocytes include respiration capacity measurements of
preadipocyte cultures or isolated mitochondria by Seahorse extracellu-
lar flux analyzer58,172 or respirometry analyses from isolated mito-
chondria or adipocytes by Oroboros O2K high‐resolution
respirometry.58,67,71 Spectrophotometric analyses of isolated respira-
tory chain complex activities have also been used to assess OXPHOS
activity.74,81 Also, single enzyme activities in pathways other than
OXPHOS, such as citrate synthase activity,58,60,67,71 have been used
as an indicator of mitochondrial activity.
Indirect ways of studying mitochondria include methods, where
the oxygen consumption of the tissues is calculated through measur-
ing blood flow in the tissue,111,112 through the inorganic phosphate
utilization of mitochondria74 or other metabolites entering and formed
in adipose tissue or cultured preadipocytes by spectrophotometric
assays: ATP content,80 fumarate, succinate,185 or other
mitochondria‐related metabolites.4.14 | Interventions to enhance mitochondrial
biogenesis in AT
Enhancing mitochondrial amount or function in adipose tissue may
help with addressing the metabolic complications of obesity.
Some pharmacological interventions that have already been
tested to treat insulin resistance could increase mitochondrial bio-
genesis in obesity. PPARγ‐agonist thiazolidinediones (TZDs) have
HEINONEN ET AL.14 23ofbeen used to treat patients with type 2 diabetes. These agents
improve the insulin sensitivity of adipose and other tissues. TZDs
appear to increase mitochondrial biogenesis, function, and content.
They improve oxidative capacity in adipocytes in mice and upregu-
late mitochondria‐associated genes, mtDNA amount, and PGC‐
1α.57,149 In humans, evidence of this has also been shown
in vitro214 and in vivo, where treatment with pioglitazone improved
mitochondrial biogenesis in patients with diabetes by stimulating the
expression of genes important for fatty acid oxidation and PGC‐1α
and by increasing mitochondrial copy number.66 However,
rosiglitazone from the same TZD group caused cardiovascular prob-
lems, which led to its withdrawal from use.215,216 In humans, treat-
ment with vitamin D217 reduced oxidative stress and improved
insulin sensitivity. Vitamin E in mice activated PPARalpha, the medi-
ator of mitochondrial fatty acid oxidation, and improved insulin sen-
sitivity.218 R‐alpha‐lipoic acid and acetyl‐L‐carnitine enhanced
mitochondrial biogenesis and fatty‐acid oxidation in cultured mouse
adipocytes.219 The same compounds have resulted in improvement
in insulin sensitivity in human studies, although no relation to mito-
chondria was studied.220,221 However, other human studies have
failed to show the association between antioxidants and improved
metabolism.222,223 Chemical uncouplers that dissipate the energy
produced by mitochondria as heat have led to weight loss224 but
also to uncontrolled thermogenesis with fatal increases in body tem-
perature.225 Use of chemical uncouplers has thus discontinued. In
muscle studies, exercise226,227 (with PGC‐1α and VEGFA upregula-
tion228) and caloric restriction in muscle and adipose tissue (AMPK
and SIRT1 as the principal modulators229,230) appear to improve
mitochondrial biogenesis. However, data from adipose tissue are still
sparse. In mouse studies, resveratrol and other small‐molecule com-
pounds that activate SIRT1 have led to improvement in insulin sen-
sitivity in adipose tissue, muscle, and liver231,232 and increased the
expression of mitochondria‐related genes in liver and muscle
tissue.232
Bariatric surgery has also emerged as a possibility to improve
metabolic health in obesity. After surgery, insulin‐resistant individ-
uals exhibit increased levels of mitofilin (a regulator of mitochondrial
membrane architecture), increased PGC‐1α protein levels, and upreg-
ulation of mitochondrial superoxide dismutase.233 In normoglycaemic
individuals, mitofilin and PGC‐1α were already high before bariatric
surgery and decreased afterwards.233 Bariatric surgery may thus
enhance mitochondrial biogenesis, activity, and antioxidant defences
in adipose tissue of insulin‐resistant subjects with obesity, but more
studies on this are still needed.
Obesity is a multisystemic and multifactorial disease. Personalized
therapies will be needed to treat individuals with obesity with
different metabolic status and to administer drugs locally.234
Targeting mitochondrial metabolism may decrease insulin resistance
and inflammation and enhance preadipocyte differentiation in
adipose tissue with beneficial effects in the treatment of obesity.
Targeted antioxidant supplements, mild and safe mitochondrial
uncoupling agents with thiazolidinedione‐type drugs, or both may be
beneficial.5 | CONCLUSIONS
Normal mitochondrial function has central effects on the health and
function of adipose tissue. The downregulation of mitochondrial oxi-
dative metabolism in obesity has been shown in many animal and
human studies, involving both adipose tissue and adipocytes, with
changes in gene expression as well as in the methylation pattern of
the cells. Disruptions in adipocyte mitochondrial function and
increased demand for FFA and glucose disposal in obesity lead to
enhanced lipid deposition in the cell.145 This may lead to enhanced
stress, accumulation of intermediary metabolites, increased inflamma-
tion and ROS, and reduced mitochondrial biogenesis. This can further
lead to reduction in adipogenesis, oxidative metabolism, and insulin
sensitivity of the cells,2,4 as well as to inflammation. If adipose tissue
and its mitochondria are dysfunctional and the storage capacity of adi-
pocytes is compromised, FFA spill over to ectopic sites in the liver,
muscle, and pancreas causing dysfunction and insulin resistance.235
Mitochondrial dysfunction also reduces the synthesis of
adiponectin.137-139 Adipose tissue dysfunction has been recognized
as an important contributor to obesity‐related disorders5,6 and can
increase the risk of developing insulin resistance and metabolic com-
plications of obesity.9,236 In the light of these findings, it seems plausi-
ble to suggest mitochondria as one of the underlying causes behind
the metabolic complications that develop during obesity. (Figure 4)
Based on current knowledge, there is a widespread downregula-
tion of adipose tissue mitochondria in obesity, although with some
controversy on the causal relationships between low mitochondrial
oxidative function with inflammation, insulin resistance, and deranged
differentiation of cells. These aspects require more follow‐up studies
in humans. Downregulation of mitochondrial function or biogenesis
in obesity has long‐term consequences for the metabolism of adipose
tissue and the whole body. (Figure 4)
Future research on understanding the exact pathways that lead to
mitochondrial dysfunction in adipose tissue in obesity and revealing
possible targets for pharmacological or nutritional interventions to
enhance mitochondrial biogenesis or function in obesity is warranted.
Distinguishing the individuals most prone to the metabolic problems
of obesity and who would gain most of the interventions will be an
important future target.62,94 More mechanistical studies are needed
on the relationship of mitochondrial function, inflammation, and insu-
lin resistance to be able to answer this need.
Mitochondria in white adipose tissue may in future be pharmaco-
logically modified to enhance their function and amount and provide
metabolic benefits for people with obesity. Compounds already iden-
tified for this purpose include agonists for the PPARs and ERRs, SIRT1,
TGR5, and AMPK.237 However, these compounds only target one spe-
cific site in a complex network, and thus, compounds with a broader
effect, targeting many dysfunctional sites, should be identified with
computer‐based methods.237 These compounds can include ones that
restore mitochondrial function and also those that are toxic to mito-
chondria and should be avoided.237
Specific diets to promote mitochondrial function may be studied.
The types and amount of exercise to elicit best benefits for adipose
HEINONEN ET AL. 15  23oftissue mitochondria may be investigated.238 Imitating interventions
like bariatric surgery that seem to preserve a favourable metabolic
profile in adipose tissue should be investigated further. Combining dif-
ferent strategies will be a key issue in combating a multifactorial dis-
ease like obesity.
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